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Abstract: Kidney is an important organ to clear neurotoxic
substance in circulation. However, it is still unknown about the
effect of renal function impairment (RFI) on the mortality of
cirrhotic patients with hepatic encephalopathy (HE). We used the
Taiwan National Health Insurance Database to identify 4932 cirrhot-
ic patients with HE, hospitalized between January 1, 2007 and
December 31, 2007. The enrolled patients were followed up
individually for 3 years to identify their 3-year mortalities. There
were 411 (8.3%) patients with RFI and 4521 (91.7%) patients
without RFI. The adjusted hazard ratio (HR) of RFI for 3-year
mortality was 2.03 (95% CI, 1.82–2.27). In RFI group, there were
157 (38.2%) patients with acute renal failure (ARF), 61 (14.8%)
with hepatorenal syndrome (HRS), 93 (22.6%) with chronic kidney
disease (CKD), and 100 (24.3%) with end-stage renal disease
(ESRD). Compared with the non-RFI group, the adjusted HR of
ARF for 3-year mortality was 2.57 (95% CI, 2.17–3.06), CKD 1.93
(95% CI, 1.55–2.40), ESRD 1.26 (95% CI, 1.01–1.57), and HRS
3.58 (95% CI, 2.78–4.63). Among ESRD patients, there were 99
patients receiving hemodialysis regularly. Compared with the CKD
group, the adjusted HR of ESRD with hemodialysis for 3-year
mortality was 0.664 (95% CI, 0.466–0.945). RFI increased the
3-year mortality of cirrhotic patients with HE, especially ARF and
HRS. HE patients with ESRD receiving hemodialysis had better
3-year survival rate than those with CKD.
(Medicine 93(14):e79)
Abbreviations: ARF = acute renal failure, CI = confidence
interval, CKD = chronic kidney disease, ESRD = end-stage
renal disease, EVB = esophageal variceal bleeding, HCC =
hepatocellular carcinoma, HE = hepatic encephalopathy, HR
= hazard ratio, HRS = hepatorenal syndrome, ICD-9-CM =
International Classification of Diseases, 9th Revision, Clinical
Modification code, NHIRD = National Health Insurance
Research Database, PUB = peptic ulcer bleeding.
INTRODUCTION
In decompensated cirrhosis, the endogenous neurotoxic sub-stances, such as ammonia, glutamine, methionine, serotonin,
benzodiazepines, and gamma-amino-butyric acid, escape ca-
tabolism from the liver. Elevated neurotoxic substances in
systemic circulation pass through blood–brain barriers and
reach brain parenchyma to impair cerebral function, which is
called hepatic encephalopathy (HE).1,2 The incidence of HE
was 2%–20% per year in patients with decompensated cirrho-
sis.3,4 Once cirrhotic patients have HE, their prognosis rapidly
worsens. Without liver transplantation, their 1-year survival
rate is 40%–50%, and the 3-year survival rate is only 23%.5,6
The common precipitating factors of HE included infec-
tion, gastrointestinal bleeding, and constipation.6–10 Kidney is
an important organ to clear bloodstream ammonia that
increases the susceptibility to brain edema.11–13 In previous
studies, acute renal failure (ARF) is an unfavorable prognostic
factor for 30-day mortality of HE patients.6,7 However, other
forms of renal function impairment (RFI), including end-stage
renal disease (ESRD), chronic kidney disease (CKD), and
hepatorenal syndrome (HRS), has not been well studied, and
their effects on the mortality of HE patients have still been
inconclusive. We used Taiwan’s nationwide population-based
dataset to enroll a large population of cirrhotic patients with
HE. All patients were followed up individually to determine
their 3-year mortality and evaluate the effects of various forms
of RFI on their mortalities.
MATERIALS AND METHODS
Ethics Statement
This study was initiated after the approval by the
Institutional Review Board of Buddhist Dalin Tzu Chi Hospi-
tal, Chiayi, Taiwan. Since all identifying personal information
was removed from the secondary files prior to analysis, the
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review board waived the requirement for written informed
consent from the patients whose data were involved.
Database
This de-identified database used in this study was from
the National Health Insurance Research Database (NHIRD),
Taiwan, established and maintained by the Taiwan National
Health Insurance Bureau and the National Health Research
Institute. The dataset in this study is from this database,
which includes all diagnostic coding information of the
hospitalized patients in Taiwan. The Taiwan National Health
Insurance Program was developed in 1995 and included all
citizens living in Taiwan; this program covers more than
99% of Taiwan’s population. Many articles have been
published based on the NHIRD.14,15 The privacy of the
patients was protected, and all the study protocols needed to
be evaluated by the National Health Research Institute. This
study was approved by the National Health Research
Institute (application and agreement number 101516).
Study Sample
This retrospective study included the patients discharged
with the diagnosis of cirrhosis (International Classification of
Diseases, 9th Revision, Clinical Modification code [ICD-9-
CM] 571.5, or 571.2 in the database) between January 1,
2007 and December 31, 2007. In this situation, the cirrhotic
patients with HE (ICD-9-CM code 572.2) were enrolled for
evaluation.16 In the cases of multiple hospitalizations, only
the first episode was included. The patients receiving liver
transplantation were excluded. Finally, a total of 4932
cirrhotic patients with HE were enrolled. They were divided
into RFI group and non-RFI group. They were followed up
individually for 3 years to identify their 3-year mortalities.
The patients with RFI were defined as those with diagnosis
codes related to RFI (ICD-9-CM codes 584, 585, 586, and
572.4, or other procedure codes related to renal failure).17
We stratified the RFI patients into four groups, including
ESRD, ARF, HRS, and CKD. ESRD was defined as the patients
receiving long-term hemodialysis or peritoneal dialysis before
admission for HE. In our country, the patients with long-term
dialysis had a certification to reduce their medical payment. An
isolated dataset from the NHIRD could be used to identify the
patients with long-term dialysis. HRS was defined as a patient
with the ICD-9-CM diagnosis code of 572.4. ARF was defined as
a patient with the ICD-9-CM diagnosis codes of 584, and without
572.4. Except for the patients with ESRD, HRS, or ARF, the
patients with the ICD-9-CM diagnosis code of 585 were
identified as the patients with CKD, not requiring long-term
dialysis before admission for HE. Because the ICD-9-CM
diagnosis code of 586 is an obscure code for renal failure, we
reviewed the other diagnosis and procedure codes for those
patients to identify if they had ARF, CKD, HRS, or ESRD. In
order to reduce the possibility of wrong coding or classification,
we reviewed all diagnosis and procedure codes in every hospitali-
zation before the time of enrolling in all enrolled RFI patients.
In order to regress the effect of RFI on the mortality
of cirrhotic patients with HE, we selected the mortality-
related factors as comorbid medical factors, including
alcoholism (ICD-9-CM codes 291, 303, 305.00–305.03,
571.0–571.3), hepatocellular carcinoma (HCC) (ICD-9-CM
code 155.0), peptic ulcer bleeding (PUB) (ICD-9-CM codes
531.0, 531.2, 531.4, 531.6, 532.0, 532.2, 532.4, 532.6,
533.0, 533.2, 533.4, and 533.6), esophageal variceal bleed-
ing (EVB) (ICD-9-CM codes 456.0, 456.20), ascites (ICD-
9-CM code 789.5, or procedure code 54.91), and bacterial
infections. The bacterial infections included pneumonia
(ICD-9-CM codes 481–487, without 484),18 liver abscess
(ICD-9-CM code 572.0), empyema (ICD-9-CM code 510),
cellulitis (ICD-9-CM code 681 or 682), necrotizing fasciitis
(ICD-9-CM code 728.86), central nerve system infection
(including bacterial meningitis or brain abscess; ICD-9-CM
code 324 or 320), sepsis (ICD-9-CM codes 038, 020.0,
790.7, or 112.81),19 infective endocarditis (ICD-9-CM code
421), urinary tract infection (ICD-9-CM code 590.1, 595.0,
595.9, or 599.0),20 biliary tract infection or acute cholecys-
titis (ICD-9-CM codes 576.1, 575.0, 574.00, 574.01,
574.30, 574.31, 574.60, 574.61, 574.80, and 574.81), septic
arthritis (ICD-9-CM code 711), perianal abscess (ICD-9-CM
code 566), and spontaneous bacterial peritonitis. Spontane-
ous bacterial peritonitis was defined as a patient with the
ICD-9-CM diagnosis code 567.2, 567.8, or 567.9, and
without the procedure codes for the abdominal surgery.21,22
In addition to the diagnosis codes mentioned above, we
checked all diagnosis codes of the enrolled patients to
confirm if the patients have bacterial infections.
Statistical Analyses
The SPSS statistical package (SPSS System for
Windows, version 12.0, SPSS Inc, Chicago, IL) was used
for statistical analysis. The Student t test was used to
TABLE 1. Demographic Characteristics of Cirrhotic Patients Having Hepatic Encephalopathy With and Without Renal
Function Impairment
RFI
(N¼ 411)
Non-RFI
(N¼ 4521) P Value
Male, N (%) 274 (66.7) 3227 (71.4) 0.044
Age, y 60.2 13.8 57.0 14.1 <0.001
EVB, N (%) 39 (9.5) 564 (12.5) 0.077
Alcohol related, N (%) 87 (21.2) 1465 (32.4) <0.001
HCC, N (%) 84 (20.4) 970 (21.5) 0.630
Infection, N (%) 119 (29.0) 1227 (27.1) 0.429
PUB, N (%) 20 (4.9) 244 (5.4) 0.647
Ascites, N (%) 128 (31.1) 1296 (28.7) 0.289
EVB¼ esophageal varices bleeding, HCC¼ hepatocellular carcinoma, PUB¼ peptic ulcer bleeding, RFI¼ renal function impairment.
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compare continuous variables, and the chi square test was
used to compare categorical variables. In order to identify
risk factors for the mortality, the proportional hazards Cox
regression model was used to control for possible confound-
ing factors. We present hazard ratios (HRs) with the 95%
confidence intervals (CIs) using a significance level of P
value <0.05. The starting point to evaluate the 3-year
mortalities in the cirrhotic patients with HE was the
admission date of the enrolled hospitalization.
RESULTS
Of the total 4932 cirrhotic patients with HE, the mean
age was 57.2 14.1 years and 3499 (71.0%) were male. The
demographic characteristics of HE patients with and without
RFI are listed in Table 1. There were 411 patients with RFI
and 4521 patients without RFI. The patients with RFI were
older than those without RFI. More patients were male and
alcohol related in the non-RFI group. The overall 30-day,
90-day, 1-year, and 3-year mortalities in the RFI group were
36.6%, 59.5%, 76.6%, and 89%, respectively. The overall
30-day, 90-day, 1-year, and 3-year mortalities in the non-RFI
group were 16.4%, 28.3%, 49.1%, and 70.1%, respectively
(P< 0.001).
The results of Cox regression analysis of HR for the
predisposing factors of 3-year mortality are provided in
Table 2. After adjusting for the patients’ gender, age, and
other comorbid disorders, the adjusted HR of RFI for 3-
year mortality was 2.03 (95% CI, 1.82–2.27; P< 0.001).
Figure 1 shows the cumulative survival plot for HE
patients with and without RFI. Other factors positively
associated with 3-year mortality of HE patients included
HCC (HR 2.18; 95% CI, 2.02–2.37; P< 0.001), EVB (HR
1.25; 95% CI, 1.13–1.39; P< 0.001), age (HR 1.02; 95%
CI, 1.00–1.02; P< 0.001), male gender (HR 1.09; 95% CI,
1.00–1.17; P¼ 0.042), bacterial infection (HR, 1.32; 95%
CI, 1.22–1.84; P< 0.001), and ascites (HR, 1.48; 95% CI,
1.38–1.59; P< 0.001). Alcohol-related cirrhosis (HR 0.84;
95% CI, 0.77–0.91; P< 0.001) was negatively associated,
and PUB (HR 0.94; 95% CI, 081–1.10; P¼ 0.439) was
not associated with the 3-year mortality of HE patients.
In the RFI group, there were 157 (38.2%) patients with
ARF, 61 (14.8%) with HRS, 93 (22.6%) with CKD, and 100
(24.3%) with ESRD. After Cox regression model, the results
of HRs of subgroups for the 3-year mortality of HE patients
are shown in Table 3. Compared with the non-RFI group,
the adjusted HRs of ARF, CKD, HRS, and ESRD was 2.57
(95% CI, 2.17–3.06; P< 0.001), 1.93 (95% CI, 1.55–2.40;
TABLE 2. Adjusted Hazard Ratios for 3-Year Mortality in Cirrhotic Patients With Hepatic Encephalopathy
Variable HR 95% CI P Value
RFI 2.03 1.82–2.27 <0.001
Age 1.02 1.00–1.02 <0.001
Male 1.09 1.00–1.17 0.042
Alcohol related 0.84 0.77–0.91 <0.001
Infection 1.32 1.22–1.84 <0.001
PUB 0.94 0.81–1.10 0.439
Ascites 1.48 1.38–1.59 <0.001
EVB 1.25 1.13–1.39 <0.001
HCC 2.18 2.02–2.37 <0.001
CI¼ confidence interval, EVB¼ esophageal varices bleeding, HCC¼ hepatocellular carcinoma, HR¼ hazard ratio, PUB¼ peptic ulcer
bleeding, RFI¼ renal function impairment.
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FIGURE 1. Cumulative survival plot for cirrhotic patients having hepatic encephalopathy with and without renal function impairment.
ã 2014 Lippincott Williams & Wilkins www.md-journal.com | 3
Medicine • Volume 93, Number 14, September 2014 Renal Function Impairment and Hepatic Encephalopathy
P< 0.001), 3.58 (95% CI, 2.78–4.63; P< 0.001), and 1.26
(95% CI, 1.01–1.57; P¼ 0.044), respectively. Figure 2 shows
the cumulative survival plot for HE patients with ARF, HRS,
ESRD, and CKD. Interestingly, we found that CKD patients
had higher HR than ESRD patients.
In the ARF group, there were 32 patients receiving
hemodialysis in their hospitalizations. Compared with the
ARF without hemodialysis, the adjusted HRs of ARF
with hemodialysis for the 3-year mortality was 1.278
(95% CI, 0.813–2.008; P¼ 0.287). Hemodialysis for ARF
in HE patients did not show a better survival. In HRS
group, all patients received standard treatment for HRS,
including terlipressin and albumin, and no one received
hemodialysis in their hospitalizations. In ESRD group, only
1 patient received peritoneal dialysis and the remaining 99
patients received hemodialysis. In order to identify if ESRD
patients with hemodialysis have a better survival than CKD
patients, we performed Cox regression model adjusted by age,
gender, and other comorbid disorders in HE patients with
ESRD and CKD. Compared with the CKD, the HR of ESRD
with hemodialysis for the 3-year mortality was 0.664 (95% CI,
0.466–0.945, P¼ 0.023) (Table 4).
DISCUSSION
To our best knowledge, this is the first nationwide
population-based study to identify the effect of RFI on the
outcomes of cirrhotic patients with HE. Using the nationwide
population-based database to enroll a large population of HE
patients, our study provides reliable information and reflects
the real mortality in recent clinical practice. In previous
studies, RFI has been confirmed to be an important predictor
of the mortality of cirrhotic patients with spontaneous bacterial
peritonitis.17,23,24 The current study shows that RFI is also an
TABLE 3. Adjusted Hazard Ratios of Different Types of Renal Function Impairment for 3-Year Mortality of Cirrhotic Patients
With Hepatic Encephalopathy Compared With Nonrenal Function Impairment Group
Variables Number (%) HR 95% CI P Value
ARFa 157 (38.2) 2.57 2.17–3.06 <0.001
CKDb 93 (22.6) 1.93 1.55–2.40 <0.001
ESRDc 100 (24.3) 1.26 1.01–1.57 0.044
HRS 61 (14.8) 3.58 2.78–4.63 <0.001
ARF¼ acute renal failure, CI¼ confidence interval, CKD¼ chronic kidney disease, ESRD¼ end-stage renal disease, HR¼ hazard ratio,
HRS¼ hepatorenal syndrome.
aThe ARF did not include HRS.
bThe CKD group included the patients with chronic renal function impairment, not requiring dialysis before admission for hepatic
encephalopathy.
cThe ESRD group included the patients requiring dialysis. HR was adjusted by patient’s gender, age, hepatocellular carcinoma, esophageal
varices bleeding, peptic ulcer bleeding, ascites, infection, and alcoholism.
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FIGURE 2. Cumulative survival plot for cirrhotic patients having hepatic encephalopathy with acute renal failure (ARF), hepatorenal
syndrome (HRS), end-stage renal disease (ESRD), and chronic kidney disease (CKD), and those without renal function impairment (RFI).
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important unfavorable factor for the mortality of cirrhotic
patients with HE. The HE patients with RFI had a 2-fold
increase in the 3-year mortality, and 90% of them died within
3 years. The other predisposing factors for the mortality of HE
patients were age, ascites, HCC, bacterial infections, and EVB.
This effect of RFI may be attributed to poor clearance of
bloodstream ammonia that increases the susceptibility to brain
edema in cirrhotic patients with HE.11–13
In this study, we separated HRS from other forms of
RFI. HRS is a very specific form of RFI in cirrhotic patients.
It is caused by splanchnic arterial vasodilation in cirrhotic
patients, and featured by a marked renal vasoconstriction
with a consequent reduction in renal plasma flow and
glomerular filtration rate, absence of pathologic changes in
the kidney tissue, and intact activity of renal tubules.25,26
The clinical diagnosis of HRS was based on the criteria
established by the International Ascites Club.27 We found
that the effect of HRS and ARF on the mortality of cirrhotic
patients with HE was similar within first 1 month. However,
unlike ARF group, the slope of survival curve of HRS did
not become gentle after 1 month. This phenomenon reflects
that the effect of HRS was more persistent than ARF in
cirrhotic patients with HE.
Interestingly, the current study showed that the HE
patients with ESRD receiving hemodialysis had better survival
than the HE patients with CKD. Theoretically, the CKD
patients had better reserve of renal function than the ESRD
patients. The formers were speculated to have better survival
than the latters. However, the result did not agree this
ratiocination. We consider that hemodialysis plays an impor-
tant role for the better survival in HE patients with ESRD. In
HE patients, arterial ammonia concentration is correlated with
occurrence of cerebral herniation and increases of intracranial
pressure.28 The patients treated with dialysis, including perito-
neal dialysis, hemodialysis, and hemofiltration, can eliminate
water-soluble substances, including ammonia, creatinine, and
urea. In previous studies, standard hemodialysis and charcoal
hemoperfusion have both been shown to lower serum ammonia
levels and lead to clinical improvement in patients with
hyperammonemic encephalopathy.29,30 This may be reason
why HE patients with ESRD receiving hemodialysis had better
survivals than those with CKD. However, it needs further
prospective study to prove this theory.
Different hospital levels have different therapeutic strate-
gies for cirrhotic patients with HE, which may have some
impacts on the mortality of HE patients. Our study is the first
nationwide study to identify the effects of RFI on the mortal-
ities of cirrhotic patients with HE. The used database included
all HE patients hospitalized in a variety of hospitals in Taiwan.
This can prevent selection bias caused by the single-center
study. We also reported an overall mortality for cirrhotic
patients with HE, including both in and out-of-hospital
mortality. This prevented underestimating the mortality, which
is possible in studies that include only in-hospital mortality.
Nonetheless, there were several limitations in our study. First,
although the severity of cirrhosis was commonly based by
Child-Pugh score or Mayo Clinic model for end-stage liver
disease score, it was not possible to identify the laboratory data
such as bilirubin, albumin, prothrombin time, or creatinine by
ICD-9 coding numbers in this database. However, the Child-
Pugh or Mayo Clinic model for end-stage liver disease score in
HE patients was not shown to be associated with outcome in
previous studies.31 Second, about 31.5% of cirrhotic patients in
our study were alcohol related. However, the exact etiology of
nonalcoholic liver cirrhosis could not be identified in this
population-based study. However, the etiology of nonalcohol-
related cirrhosis in Taiwan is mostly known to be related to the
hepatitis B virus and has been well established in the previous
published reports,32 and the etiology of nonalcoholic liver
cirrhosis cannot be confirmed as a prognostic factor on
survival in cirrhotic patients with HE. Finally, the grade of HE
was not possible to be evaluated in this database. However, the
grade of HE seems not to be an independent prognostic factor
in in-hospital mortality.7,31 Udayakumar et al31 reported that
mild or severe grade of encephalopathy did not predict the
mortality in chronic liver disease. In the report by Shawcross
et al,7 patient survival stratified according to the degree of
encephalopathy grade 3 or 4 also did not reveal statistically
difference.
Despite these limitations, this nationwide population-
based study identified RFI as an important risk factor
for the 3-year mortality of cirrhotic patients with HE.
RFI increases 2-fold of the mortality in cirrhotic patients
with HE. In HE patients with RFI, the HRS patients had
the worst outcome. The HE patients with ESRD receiv-
ing hemodialysis had better survival than those with
CKD.
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